The most common adverse reactions (ARs) in ≥5% of subjects2

  • Derived from 3 clinical trials in which 339 patients received the DEXYCU 517-mcg dose1
  • The most commonly reported ARs in 5%-15% of subjects included increases in IOP, corneal edema, and iritis1
  • Other ocular ARs occurring in 1%-5% of subjects included corneal endothelial cell loss, blepharitis, eye pain, cystoid macular edema, dry eye, ocular inflammation, posterior capsule opacification, blurred vision, reduced visual acuity, vitreous floaters, foreign body sensation, photophobia, and vitreous detachment1